Investors Take Action: Pomerantz Law Firm Files Class Action Against Ardent Health, Inc.

Investor Alert: Class Action Lawsuit Against Ardent Health, Inc.

On February 12, 2026, Pomerantz LLP made a significant announcement regarding Ardent Health, Inc. (NYSE: ARDT), informing investors of a newly filed class action lawsuit. This legal action is intended for individuals who suffered losses on their investment in the company during the specified Class Period.

Details of the Lawsuit

The class action lawsuit aims to address potential securities fraud or other unlawful business practices by Ardent and its leadership team. Investors affected by these issues are strongly urged to reach out to Danielle Peyton at Pomerantz to enlist in the lawsuit and possibly become the Lead Plaintiff. Interested parties can contact via email at [email protected] or call 646-581-9980, toll-free extensions also available.

Key Dates

The deadline for investors to submit their request to be appointed as Lead Plaintiff is March 9, 2026. Those who wish to become involved are encouraged to provide their mailing address, contact number, and details of the shares they purchased. Further information, including a copy of the Complaint, is available on the Pomerantz Law website.

Background Context

The class action follows alarming revelations from Ardent Health that surfaced in November 2025, when the company reported a staggering $43 million drop in its third-quarter revenue. This decline stemmed from adjustments in the accounts receivable collectibility process that resulted from their transition to a new revenue accounting system, the Kodiak RCA net revenue platform.

Ardent’s new accounting system aimed to enhance the accuracy of revenue collection assessments. However, the implementation led to a re-evaluation of historical collection trends and caused a shift in reserve recognition for accounts receivable. As a result, the company adjusted its expected EBITDA guidance for 2025, cutting it by approximately 9.6% due to ongoing pressures in the industry, including payer denials.

Further complicating matters, Ardent announced its need to increase professional liability reserves by $54 million following recent settlements and ongoing legal disputes from claims dating back to 2019-2022. These cumulative factors took a toll on Ardent’s stock, which plunged by 33.81% to close at $9.30 on November 13, 2025, signaling deep investor concern over the company's financial integrity and operational strategies.

About Pomerantz LLP

With a legacy exceeding 85 years, Pomerantz LLP, headquartered in New York and with additional offices in Chicago, Los Angeles, London, Paris, and Tel Aviv, enjoys a reputation as a leading firm in the realm of corporate and securities class litigation. The firm has consistently fought for the rights of investors against major corporate misconduct, recovering significant compensation for class members over the years.

Moving Forward

As this class-action lawsuit unfolds, it serves as a crucial reminder for investors in Ardent Health and the wider market of the inherent risks associated with equity investments. Those affected are encouraged to seek legal guidance promptly and stay informed about ongoing developments in this situation.

For additional information regarding the lawsuit against Ardent Health or to learn more about your rights as an investor, visit Pomerantz Law Firm's website.